MCID: LMN006
MIFTS: 39

Luminal Breast Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma

MalaCards integrated aliases for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma 12 15
Breast Tumor Luminal 12 17
Luminal Breast Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as breast tumor luminal, is related to estrogen-receptor positive breast cancer and breast ductal carcinoma. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are Pathways in cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Letrozole and Vitamin D have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 30.2 TP53 PIK3CA PGR MTOR GATA3 FOXA1
2 breast ductal carcinoma 30.2 TP53 PGR KRT5 ESR1 ERBB2 EGFR
3 in situ carcinoma 30.0 TP53 PGR MIR342 KRT5 H2AC18 ESR1
4 breast adenocarcinoma 30.0 TP53 PIK3CA PGR LCOR H2AC18 ESR1
5 ductal carcinoma in situ 30.0 TP53 PIK3CA PGR KRT5 ESR1 ERBB2
6 leukemia, acute myeloid 29.8 TP53 MTOR MIR21 LCOR KDM4C H2AC18
7 breast cancer 29.4 TP53 PIK3CA PGR MTOR MIR342 MIR21
8 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1
9 chronic tympanitis 10.7 PGR ESR1
10 scirrhous adenocarcinoma 10.7 PGR ERBB2
11 granulomatous endometritis 10.7 PGR ESR1
12 glassy cell carcinoma of the cervix 10.7 PGR ESR1 ERBB2
13 breast juvenile papillomatosis 10.7 PGR ESR1 ERBB2
14 lung leiomyoma 10.7 PGR ESR1
15 vulvar syringoma 10.7 PGR ESR1
16 oncocytic breast carcinoma 10.7 PGR ESR1 ERBB2
17 trigonitis 10.7 PGR ESR1
18 breast cystic hypersecretory carcinoma 10.7 KRT5 ERBB2
19 inverted transitional papilloma 10.7 KRT5 GATA3
20 lipid-rich breast carcinoma 10.6 PGR KRT5 ERBB2
21 breast neuroendocrine neoplasm 10.6 PGR ESR1 ERBB2
22 vagina leiomyosarcoma 10.6 PGR ESR1
23 leiomyomatosis 10.6 PGR KDM4C ESR1
24 paronychia 10.6 MTOR ERBB2 EGFR
25 recurrent respiratory papillomatosis 10.6 ERBB2 EGFR
26 benign breast adenomyoepithelioma 10.6 KRT5 EGFR
27 breast mucinous carcinoma 10.6 PGR KRT5 ERBB2
28 vulva basal cell carcinoma 10.6 KRT5 ERBB2
29 adult type testicular granulosa cell tumor 10.6 PGR ESR1
30 cervical serous adenocarcinoma 10.6 PGR GATA3
31 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
32 breast leiomyoma 10.6 PGR ESR1
33 microinvasive cervical squamous cell carcinoma 10.6 KRT5 GATA3
34 malignant spiradenoma 10.6 TP53 KRT5
35 rare head and neck tumor 10.6 TP53 PIK3CA
36 mucoepidermoid esophageal carcinoma 10.6 TP53 KRT5
37 bartholin's gland adenoma 10.6 TP53 PGR ESR1
38 bartholin's gland benign neoplasm 10.6 TP53 PGR ESR1
39 sweat gland neoplasm 10.6 TP53 KRT5 ERBB2
40 vestibular gland benign neoplasm 10.6 TP53 PGR ESR1
41 pregnancy adenoma 10.6 PGR KRT5
42 apocrine adenosis of breast 10.6 TP53 PGR ERBB2
43 external ear carcinoma 10.6 PGR KRT5
44 ovarian seromucinous carcinoma 10.6 TP53 PGR ESR1
45 mammographic density 10.6 PGR ESR1 CYP19A1
46 gastric diffuse adenocarcinoma 10.6 TP53 PGR ERBB2
47 bizarre leiomyoma 10.6 TP53 PGR ESR1
48 gender identity disorder 10.6 PGR ESR1 CYP19A1
49 juvenile nasopharyngeal angiofibroma 10.6 PGR ESR1 CYP19A1
50 large cell acanthoma 10.6 TP53 MTOR KRT5

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:



Diseases related to Luminal Breast Carcinoma

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10 EGFR MTOR PIK3CA
2 Decreased viability GR00221-A-1 10 EGFR ESR1 MTOR PIK3CA
3 Decreased viability GR00221-A-2 10 ESR1 PIK3CA
4 Decreased viability GR00221-A-3 10 ERBB2
5 Decreased viability GR00221-A-4 10 EGFR ERBB2 ESR1 MTOR PIK3CA
6 Decreased viability GR00342-S-1 10 MTOR
7 Decreased viability GR00342-S-2 10 MTOR
8 Decreased viability GR00402-S-2 10 EGFR ERBB2 ESR1 MTOR PIK3CA
9 Decreased viability with paclitaxel GR00179-A-1 9.36 EGFR MTOR ERBB2
10 Decreased viability with paclitaxel GR00179-A-2 9.36 MTOR
11 Decreased viability with paclitaxel GR00179-A-3 9.36 EGFR MTOR

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.27 CD44 CYP19A1 EGFR ERBB2 ESR1 FOXA1
2 cellular MP:0005384 10.26 CD44 CYP19A1 EGFR ERBB2 ESR1 GATA3
3 growth/size/body region MP:0005378 10.26 CD44 CYP19A1 EGFR ERBB2 ESR1 FOXA1
4 cardiovascular system MP:0005385 10.24 CD44 CYP19A1 EGFR ERBB2 ESR1 GATA3
5 integument MP:0010771 10.21 CD44 CYP19A1 EGFR ERBB2 ESR1 FOXA1
6 immune system MP:0005387 10.2 CD44 CYP19A1 EGFR ESR1 FOXA1 GATA3
7 digestive/alimentary MP:0005381 10.16 CD44 CYP19A1 EGFR ERBB2 ESR1 FOXA1
8 adipose tissue MP:0005375 10.09 CYP19A1 EGFR ESR1 GATA3 MTOR PIK3CA
9 muscle MP:0005369 10.07 CD44 CYP19A1 EGFR ERBB2 ESR1 GATA3
10 neoplasm MP:0002006 9.97 CD44 EGFR ERBB2 ESR1 FOXA1 KDM4C
11 limbs/digits/tail MP:0005371 9.95 CD44 EGFR ERBB2 ESR1 KRT5 PGR
12 no phenotypic analysis MP:0003012 9.91 EGFR ESR1 GATA3 KDM4C KRT5 MTOR
13 normal MP:0002873 9.81 CD44 CYP19A1 EGFR ERBB2 ESR1 GATA3
14 pigmentation MP:0001186 9.35 CD44 CYP19A1 EGFR GATA3 TP53
15 skeleton MP:0005390 9.32 CD44 CYP19A1 EGFR ERBB2 ESR1 GATA3

Drugs & Therapeutics for Luminal Breast Carcinoma

Drugs for Luminal Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
2
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
3
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
4 Estrogens Phase 4
5 Aromatase Inhibitors Phase 4
6 Hormone Antagonists Phase 4
7 Hormones Phase 4
8 Estrogen Antagonists Phase 4
9 Steroid Synthesis Inhibitors Phase 4
10 Estrogen Receptor Antagonists Phase 4
11 Calcium, Dietary Phase 4
12 Calciferol Phase 4
13
Palbociclib Approved, Investigational Phase 3 571190-30-2 11431660 5005498 5330286
14
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
15
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
16 Protein Kinase Inhibitors Phase 3
17 Antineoplastic Agents, Hormonal Phase 3
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Tamoxifen Approved Phase 2 10540-29-1 2733526
20
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
21
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8
24
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
25
Phenobarbital Approved, Investigational Phase 2 50-06-6 4763
26
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
27
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
28
Epirubicin Approved Phase 2 56420-45-2 41867
29
Liposomal doxorubicin Phase 2 31703
30 Selective Estrogen Receptor Modulators Phase 2
31 Estrogen Receptor Modulators Phase 2
32 taxane Phase 2
33 Neurotransmitter Agents Phase 2
34 Cytochrome P-450 CYP3A Inducers Phase 2
35 Albumin-Bound Paclitaxel Phase 2
36 GABA Agents Phase 2
37 Antimitotic Agents Phase 2
38 Hypnotics and Sedatives Phase 2
39 Central Nervous System Depressants Phase 2
40 Excitatory Amino Acids Phase 2
41 Anticonvulsants Phase 2
42 Excitatory Amino Acid Antagonists Phase 2
43 GABA Modulators Phase 2
44 Anti-Bacterial Agents Phase 2
45 Alkylating Agents Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Topoisomerase Inhibitors Phase 2
48 Immunosuppressive Agents Phase 2
49 Antirheumatic Agents Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference? Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
2 Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant® Recruiting NCT03447132 Phase 3 Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3 A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy. Unknown status NCT02506556 Phase 2 BYl719
4 Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor Unknown status NCT02562118 Phase 1, Phase 2 Lenvatinib + Letrozole
5 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
6 Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Recruiting NCT04023292 Phase 2 Endocrine therapy;Endocrine therapy
7 Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer. Recruiting NCT03227328 Phase 2 concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy;chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
8 A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer Recruiting NCT03168074 Phase 2 lenvatinib
9 Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer Active, not recruiting NCT01565499 Phase 2 Nab-paclitaxel
10 Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
11 Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients Recruiting NCT03370250
12 Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes Recruiting NCT03761420

Search NIH Clinical Center for Luminal Breast Carcinoma

Genetic Tests for Luminal Breast Carcinoma

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

40
Breast, Bone, Lung, Ovary, Brain, Colon, Prostate

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

(show all 14)
# Title Authors PMID Year
1
DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells. 61
31130862 2019
2
First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. 61
29715116 2018
3
Age-related modifications of type I collagen impair DDR1-induced apoptosis in non-invasive breast carcinoma cells. 61
29733741 2018
4
Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. 61
28865009 2018
5
Separase is a marker for prognosis and mitotic activity in breast cancer. 61
28859055 2017
6
Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. 61
28739755 2017
7
FBP1 expression is associated with basal-like breast carcinoma. 61
28529559 2017
8
Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. 61
27511992 2016
9
Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. 61
25879784 2015
10
TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. 61
24469049 2015
11
p-mTOR expression is associated with better prognosis in luminal breast carcinoma. 61
25053543 2014
12
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. 61
24143191 2013
13
Her2 negative luminal breast carcinoma and Ki-67 evaluation. 61
22647834 2012
14
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. 61
22002565 2012

Variations for Luminal Breast Carcinoma

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1 12.75 TP53 PIK3CA MTOR ESR1 ERBB2 EGFR
2
Show member pathways
12.66 TP53 PIK3CA MTOR ERBB2 EGFR
3
Show member pathways
12.65 TP53 PIK3CA MTOR ESR1 ERBB2
4
Show member pathways
12.6 PIK3CA PGR MTOR ESR1 EGFR
5
Show member pathways
12.56 TP53 PIK3CA MTOR ERBB2 EGFR
6
Show member pathways
12.53 TP53 PIK3CA PGR MTOR ESR1 ERBB2
7
Show member pathways
12.48 TP53 PIK3CA MTOR ESR1 ERBB2 EGFR
8
Show member pathways
12.43 TP53 PIK3CA MTOR ERBB2 EGFR
9
Show member pathways
12.35 TP53 PIK3CA MTOR ERBB2 EGFR
10
Show member pathways
12.34 TP53 PIK3CA MTOR GATA3
11
Show member pathways
12.31 TP53 PIK3CA MTOR ERBB2 EGFR
12
Show member pathways
12.26 PIK3CA ESR1 ERBB2 EGFR
13 12.2 TP53 PIK3CA MTOR EGFR CD44
14
Show member pathways
12.16 TP53 PIK3CA MTOR ERBB2 EGFR
15
Show member pathways
12.06 PIK3CA MTOR ERBB2 EGFR
16
Show member pathways
11.95 TP53 PIK3CA ERBB2 EGFR
17 11.95 TP53 MTOR ESR1 EGFR CYP19A1
18 11.91 TP53 PIK3CA MTOR ESR1
19 11.87 TP53 PIK3CA MTOR MIR21 ESR1 ERBB2
20 11.82 PIK3CA MTOR ERBB2 EGFR
21 11.77 TP53 PIK3CA MTOR MIR342 MIR21 MIR19B1
22 11.74 TP53 KRT5 GATA3
23 11.69 TP53 PIK3CA ERBB2
24
Show member pathways
11.69 PIK3CA PGR ESR1 ERBB2 EGFR
25 11.68 TP53 ERBB2 EGFR
26 11.63 MTOR ESR1 EGFR
27 11.62 TP53 PIK3CA ERBB2
28 11.4 TP53 MTOR ESR1
29 11.39 TP53 PIK3CA MTOR ERBB2 EGFR
30 11.19 PIK3CA ERBB2 EGFR
31 11.16 MTOR ERBB2 EGFR
32 10.19 ESR1 CYP19A1

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.17 TP53 PGR KDM4C H2AC18 GATA3 FOXA1

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 TP53 MTOR MIR21 KDM4C GATA3 ERBB2
2 positive regulation of protein phosphorylation GO:0001934 9.8 MTOR MIR21 ERBB2 EGFR
3 regulation of transcription by RNA polymerase II GO:0006357 9.76 TP53 LCOR KDM4C GATA3 FOXA1 ESR1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 PIK3CA EGFR CD44
5 chromatin remodeling GO:0006338 9.71 KDM4C GATA3 FOXA1 ESR1
6 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PIK3CA GATA3 ERBB2
7 wound healing GO:0042060 9.62 TP53 MTOR ERBB2 EGFR
8 ERBB2 signaling pathway GO:0038128 9.61 PIK3CA ERBB2 EGFR
9 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.55 TP53 ESR1
10 anoikis GO:0043276 9.54 PIK3CA MTOR
11 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
12 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.51 TP53 ESR1
13 negative regulation of ERBB signaling pathway GO:1901185 9.48 ERBB2 EGFR
14 uterus development GO:0060065 9.43 GATA3 ESR1 CYP19A1
15 negative regulation of gene expression GO:0010629 9.43 TP53 PGR MIR21 MIR19B1 GATA3 ESR1
16 positive regulation of protein kinase B signaling GO:0051897 9.17 PIK3CA MTOR MIR21 GATA3 ESR1 ERBB2

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.72 TP53 KDM4C FOXA1 ESR1 EGFR
2 identical protein binding GO:0042802 9.7 TP53 PGR MTOR GATA3 ESR1 ERBB2
3 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.65 TP53 PGR GATA3 FOXA1 ESR1
4 protein phosphatase binding GO:0019903 9.54 TP53 ERBB2 EGFR
5 enzyme binding GO:0019899 9.02 TP53 PGR KDM4C ESR1 EGFR
6 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Luminal Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....